 | Up a level |
2018
Evers, G., Beelen, D. W., Braess, J., Sauerland, M. C., Kolb, H. J., Reichle, A., Holler, E., Schwerdtfeger, R., Arnold, R., Scheid, C., Krug, U., Mueller-Tidow, C., Schliemann, C., Mikesch, J. -H., Lenz, G., Woermann, B. J., Hiddemann, W., Berdel, W. E. and Stelljes, M. (2018). Allogeneic hematopoietic stem cell transplantation (HSCT) beyond first complete remission (CR) in patients with acute myeloid leukemia (AML): Results from the AMLCG1999 trial. Oncol. Res. Treat., 41. S. 117 - 119. BASEL: KARGER. ISSN 2296-5262
2017
Hehlmann, R., Lauseker, M., Saussele, S., Pfirrmann, M., Krause, S., Kolb, H. J., Neubauer, A., Hossfeld, D. K., Nerl, C., Gratwohl, A., Baerlocher, G. M., Heim, D., Bruemmendorf, T. H., Fabarius, A., Haferlach, C., Schlegelberger, B., Mueller, M. C., Jeromin, S., Proetel, U., Kohlbrenner, K., Voskanyan, A., Rinaldetti, S., Seifarth, W., Spiess, B., Balleisen, L., Goebeler, M. C., Haenel, M., Ho, A., Dengler, J., Falge, C., Kanz, L., Kremers, S., Burchert, A., Kneba, M., Stegelmann, F., Koehne, C. A., Lindemann, H. W., Waller, C. F., Pfreundschuh, M., Spiekermann, K., Berdel, W. E., Mueller, L., Edinger, M., Mayer, J., Beelen, D. W., Bentz, M., Link, H., Hertenstein, B., Fuchs, R., Wernli, M., Schlegel, F., Schlag, R., de Wit, M., Truemper, L., Hebart, H., Hahn, M., Thomalla, J., Scheid, C., Schafhausen, P., Verbeek, W., Eckart, M. J., Gassmann, W., Pezzutto, A., Schenk, M., Brossart, P., Geer, T., Bildat, S., Schaefer, E., Hochhaus, A. and Hasford, J. (2017). Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia, 31 (11). S. 2398 - 2407. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
2014
Kordelas, L., Verheyen, J., Beelen, D. W., Horn, P. A., Heinold, A., Kaiser, R., Trenschel, R., Schadendorf, D., Dittmer, U. and Esser, S. (2014). Shift of HIV-Tropism in a HIV-patient with large cell anaplastic T-cell-lymphoma undergoing allogeneic stem cell transplantation from a donor with homozygosity for the CCR5 delta32 mutation. Oncol. Res. Treat., 37. S. 38 - 39. BASEL: KARGER. ISSN 2296-5262